When combined with PD-1 inhibitors (e.g., Pembrolizumab), these agents help reprogram the “cold” brain metastasis microenvironment, inhibit tumor progression, and achieve high disease control rates (62, 63). The gene discussed is PDCD1; the disease is neoplasm.